Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Subbiah

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignanciesV Subbiah, N O Iannotti, M Gutierrez, et al.
ESMO Open|July 10, 2024
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignanciesM Saleh, M Barve, V Subbiah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancerV Subbiah, T Shen, M Tetzlaff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2023
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)M A Gouda, F Janku, A Wahida, et al.
ESMO Open|September 24, 2025
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter studyP Schöffski, A Gazzah, J Trigo, et al.
Investigational New Drugs|April 9, 2017
Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumorsS Fu, H Hirte, S Welch, et al.
Investigational New Drugs|February 3, 2017
First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumorsS Fu, H Hirte, S Welch, et al.
ESMO Open|November 21, 2025
First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumorsA Minchom, O Lindén, D G Knapen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2020
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutationsV Subbiah, T Shen, S S Terzyan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2025
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysisC Valenza, E F Saldanha, Y Gong, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignanciesV Subbiah, N O Iannotti, M Gutierrez, et al.
ESMO Open|July 10, 2024
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignanciesM Saleh, M Barve, V Subbiah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancerV Subbiah, T Shen, M Tetzlaff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2023
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)M A Gouda, F Janku, A Wahida, et al.
ESMO Open|September 24, 2025
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter studyP Schöffski, A Gazzah, J Trigo, et al.
Investigational New Drugs|April 9, 2017
Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumorsS Fu, H Hirte, S Welch, et al.
Investigational New Drugs|February 3, 2017
First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumorsS Fu, H Hirte, S Welch, et al.
ESMO Open|November 21, 2025
First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumorsA Minchom, O Lindén, D G Knapen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2020
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutationsV Subbiah, T Shen, S S Terzyan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2025
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysisC Valenza, E F Saldanha, Y Gong, et al.
Pageof 6